Instruction 1(b).

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
obligations may continue. See	

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Pagan Douglas W.						2. Issuer Name and Ticker or Trading Symbol ZIOPHARM ONCOLOGY INC [ZIOP]									5. Relationship of Reporting Person(s) to Issuer Check all applicable) X Director 10% Owner						
(Last)	`	irst) NCOLOGY, IN	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 09/18/2018 Officer (give title below) below) Other (specify below)											pecify				
ONE FIRST AVENUE, PARRIS BLDG. 34					4. 1	If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable						
(Street)	N M	ÍΑ	02129		_									ine) X		led by Mor		orting Persor One Repor			
(City)	(S	tate)	(Zip)																		
		Tab	le I - Noi	n-Deri	vativ	e Se	curities	s Ac	quired, D	ispo	osed o	f, or Be	nefici	ally	Owned						
Date			Date	saction n/Day/Ye	ear)	2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Disposed Code (Instr. 5)		ties Acquired (A) d Of (D) (Instr. 3, 4		and Securitie Beneficia Owned F		s ally ollowing	Form	: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership				
								Code	, .	Amount	(A) o (D)	Price	e	Reported Transact (Instr. 3 a	on(s)			(Instr. 4)			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if if any (Month/Day	Date,	4. Transa Code (8)		of		6. Date Exer Expiration E (Month/Day/	ate		7. Title an of Securit Underlyin Derivative (Instr. 3 a	ties Ig e Securit	Derivativ Security		9. Number derivative Securities Beneficial Owned Following Reported Transaction (Instr. 4)	Own S For Illy Dir Or I	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisable		piration te	Title	Amour or Number of Shares	er							
Stock Option (Right to Buy)	\$3	09/18/2018			A		50,000		(1)	09/	/18/2028	Common Stock	50,00	00	\$0.00	50,000	0	D			

Explanation of Responses:

1. 25,000 shares shall vest on each of 9/18/2019 and 9/18/2020.

Remarks:

/s/ Robert Hadfield, Attorney-

09/20/2018

in-Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.